MedTrace Logo

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT01834937 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2018-11-09

No results posted yet for this study

Summary

The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.

Conditions

  • Pain Resulting From Bone Metastases

Interventions

DEVICE

ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)

Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.

Sponsors & Collaborators

  • InSightec

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01834937 on ClinicalTrials.gov